Evidence map›Paper›PMID 34979033›Full record

ArticleAmerican journal on intellectual and developmental disabilities2022

Anxiety in Angelman Syndrome.

Stacey C Grebe, Danica L Limon, Morgan M McNeel, Andrew Guzick, Sarika U Peters, Wen-Hann Tan, Anjali Sadhwani, Carlos A Bacino, Lynne M Bird, Rodney C Samaco and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal on intellectual and developmental disabilities, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Stacey C GrebeStacey C. Grebe, Danica L. Limon, Morgan M. McNeel, and Andrew Guzick, Baylor College of Medicine.
Danica L LimonStacey C. Grebe, Danica L. Limon, Morgan M. McNeel, and Andrew Guzick, Baylor College of Medicine.
Morgan M McNeelStacey C. Grebe, Danica L. Limon, Morgan M. McNeel, and Andrew Guzick, Baylor College of Medicine.
Andrew GuzickStacey C. Grebe, Danica L. Limon, Morgan M. McNeel, and Andrew Guzick, Baylor College of Medicine.
Sarika U PetersSarika U. Peters, Vanderbilt Kennedy Center.
Wen-Hann TanWen-Hann Tan and Anjali Sadhwani, Boston Children's Hospital.
Anjali SadhwaniWen-Hann Tan and Anjali Sadhwani, Boston Children's Hospital.
Carlos A BacinoCarlos A. Bacino, Baylor College of Medicine and Texas Children's Hospital.
Lynne M BirdLynne M. Bird, University of California and Boston Children's Hospital.
Rodney C SamacoRodney C. Samaco, Baylor College of Medicine.
Leandra N BerryLeandra N. Berry, Baylor College of Medicine and Texas Children's Hospital.
Wayne K GoodmanWayne K. Goodman, Baylor College of Medicine.
Sophie C SchneiderSophie C. Schneider and Eric A. Storch, Baylor College of Medicine.
Eric A StorchSophie C. Schneider and Eric A. Storch, Baylor College of Medicine.
Baylor College of Medicine · USBoston Children's Hospital · USGoodman (Japan) · JPKennedy Center · DKTexas Children's Hospital · US

Funding

Training and Career Development ComponentU54HD061222 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PERCY, ALAN KENNETH · 2009 to 2019
$12.4M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Preclinical and Clincial OutcomesP50HD103555 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI Sandesh Chakravarthy Sreenath Nagamani, David Loren Nelson · 2020 to 2026
$9.9M
RARE DISEASE CRC FOR NEW THERAPIES AND NEW DIAGNOSTICSU54RR019478 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI BEAUDET, ARTHUR L. · 2003 to 2008
$7.3M
NCRR NIH HHS U54 RR019478NICHD NIH HHS P50 HD103537NICHD NIH HHS P50 HD103555NICHD NIH HHS U54 HD061222
6 · The paper itself

Abstract

Angelman Syndrome (AS) is a neurodevelopmental disorder most commonly caused by the impaired expression of the maternal UBE3A gene on chromosome 15. Though anxiety has been identified as a frequently present characteristic in AS, there are limited studies examining anxiety in this population. Studies of anxiety in other neurodevelopmental disorders have found disorder specific symptoms of anxiety and age specific displays of anxiety symptoms. However, there is a consistent challenge in identifying anxiety in people with neurodevelopmental disorders given the lack of measurement instruments specifically designed for this population. Given the limited information about AS and anxiety, the aims of the current project were to (a) examine symptoms of anxiety in children with AS and (b) determine the correlates of anxiety in children with AS. Participants included 42 adult caregivers of youth with AS in the AS Natural History study who completed the Developmental Behavior Checklist (DBC). The results found that 26% of the sample demonstrated elevated symptoms of anxiety and established a relationship between elevated anxiety in youth with AS and higher levels of irritability, hyperactivity, self-absorbed behaviors, and disruptive/antisocial behaviors. Findings from this research provide a foundation for tailoring evidence-based assessments and treatments for youth with AS and anxiety.

Indexed as

Angelman SyndromeNeurodevelopmental DisordersAdolescentAdultAnxietyCaregiversChecklistChildHumansAngelman syndromeanxietychildrendevelopmental behavior checklist

Identifiers

PMID34979033
PMCPMC8803540
OpenAlexW4206770805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.